Antiplatelets
High-yield Verified · Oct 2026Prototype: clopidogrel
Antiplatelets are a class of medications used for acute coronary syndrome and secondary prevention after MI.
Medical view → mechanisms, drug comparisons and Step 1 pharmacology
Agents that block platelet aggregation. The backbone of coronary-stent and post-MI care.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Two ways blood clots — and why the drug classes differ
The body forms clots two ways. In arteries, a ruptured cholesterol plaque activates platelets, which pile onto the injury — a platelet-rich white clot; platelets matter far more here than in veins. In veins, stasis favors a red clot of fibrin and red blood cells, built by the coagulation cascade.
This is why antiplatelets and anticoagulants are not interchangeable. Antiplatelets (aspirin, clopidogrel) target the arterial, platelet-driven clots behind heart attacks and ischemic strokes. Anticoagulants (warfarin, heparin, DOACs) target the cascade-driven clots of venous thrombosis (DVT/PE) and of atrial fibrillation.
02 How each antiplatelet intervenes
Platelets are activated through several signals; the drugs block different ones. Aspirin irreversibly blocks the enzyme COX-1, so platelets can’t make thromboxane A₂, a key aggregation signal — and because a platelet can’t remake the enzyme, the effect lasts the platelet’s whole ~7–10-day lifespan. Clopidogrel, prasugrel, and ticagrelor block the P2Y12 (ADP) receptor, a different activation pathway.
A crucial detail: clopidogrel and prasugrel are prodrugs — inactive until the liver converts them. Clopidogrel depends on the enzyme CYP2C19, and patients who are "poor metabolizers" activate too little drug and stay at risk (its boxed warning). Ticagrelor is not a prodrug — it blocks P2Y12 directly and reversibly, so it works regardless of CYP2C19.
The IV agents work at the end of the pathway or switch off fast. Eptifibatide and tirofiban block the glycoprotein IIb/IIIa receptor, so fibrinogen and von Willebrand factor can no longer link platelets together — whatever activated them — and the block reverses within hours of stopping. Cangrelor is an IV, direct and reversible P2Y12 blocker that needs no liver activation; its effect is gone about an hour after the infusion stops. Two older oral drugs act through the platelet’s cAMP: cilostazol inhibits phosphodiesterase III (and also dilates blood vessels), and dipyridamole blocks adenosine uptake so adenosine raises platelet cAMP.
03 Dual therapy and the stent — why you must not stop suddenly
After a coronary stent, patients take dual antiplatelet therapy (DAPT) — aspirin plus a P2Y12 blocker — to prevent a clot forming at the stent until the vessel lining grows over the stent surface (re-endothelialization). Stopping antiplatelet therapy too early raises the risk of that clot — stent thrombosis — which often leads to a heart attack or cardiac death.
That is why never stopping an antiplatelet without first talking to the prescriber is a life-or-death teaching point, and why any procedure requiring the drug to be held must be coordinated with the prescribing team.
Drug names
Indications
- Acute coronary syndrome and secondary prevention after MI
- Coronary stents — dual antiplatelet therapy (aspirin + a P2Y12 inhibitor)
- Ischemic (non-cardioembolic) stroke / TIA and peripheral arterial disease
- Eptifibatide or tirofiban IV during PCI or for non-ST-elevation ACS (GP IIb/IIIa)
- Cangrelor IV during PCI in patients not yet on a P2Y12 inhibitor
- Cilostazol for intermittent claudication — increases walking distance
- Dipyridamole with warfarin after prosthetic heart-valve replacement; combined with aspirin to reduce stroke after TIA or ischemic stroke
Mechanism of action
Aspirin irreversibly inhibits platelet COX-1, reducing thromboxane A₂. Clopidogrel, prasugrel, ticagrelor and IV cangrelor block the platelet P2Y12 (ADP) receptor — clopidogrel/prasugrel as liver-activated prodrugs, ticagrelor and cangrelor directly and reversibly. Eptifibatide and tirofiban reversibly block the glycoprotein IIb/IIIa receptor, preventing fibrinogen and von Willebrand factor binding. Cilostazol inhibits phosphodiesterase III, and dipyridamole inhibits adenosine uptake; both raise platelet cAMP. All reduce platelet aggregation.
Therapeutic effects — what you'll see working
Like anticoagulants, success is an event that never happens — no MI, no stent thrombosis, no stroke. The balance to protect is preventing arterial clots without causing dangerous bleeding.
- Prevents arterial clots
- Blocking platelet aggregation stops the platelet plug from forming on a ruptured plaque or a fresh stent, preventing MI and ischemic stroke.
- Protects the stent
- Dual therapy keeps a newly placed coronary stent from clotting off (stent thrombosis) until the vessel lining grows over the stent surface.
- Longer pain-free walking (cilostazol)
- In intermittent claudication, cilostazol increases walking distance — it inhibits platelets and also dilates arteries, more in the femoral bed. Benefit can start in 2–4 weeks but may take up to 12 weeks; if symptoms have not improved by 3 months, it is stopped.
Adverse effects
As with anticoagulants, the therapeutic effect is the danger — impairing clotting means bleeding. Aspirin adds NSAID-type GI effects; ticagrelor adds a distinctive dyspnea.
Interactions
Contraindications
Anything that makes bleeding likely — or a very recent bleed into the brain — outweighs the clot-prevention benefit.
When to hold
Assess before giving — these findings mean hold the dose and act.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Antiplatelets used for?
How do Antiplatelets work?
What are the serious side effects of Antiplatelets?
When should a nurse hold Antiplatelets, and what safety checks apply?
Conditions treated
The first drug in the door: aspirin 162–325 mg chewed (non–enteric-coated), immediately, for every suspected ACS — it blunts the platelet aggregation building the culprit thrombus. Then DAPT (aspirin + a P2Y12 inhibitor) for all ACS, continued ≥ 12 months in low-bleeding-risk patients (2025 ACC/AHA, Class 1); ticagrelor or prasugrel is preferred over clopidogrel for PCI patients — but with fibrinolysis, clopidogrel is the only P2Y12 used.
The anti-thrombus insurance: aspirin irreversibly blocks platelet cyclooxygenase → less thromboxane A₂ → less aggregation on the plaque. Low dose (81–162 mg) daily, indefinitely, in established CAD — this is secondary prevention; routine primary prevention is out (no significant event reduction, more bleeding). Clopidogrel 75 mg daily substitutes when aspirin can’t be used.
AVOID — aspirin and antiplatelet drugs impair hemostasis.
Aspirin for clot prophylaxis on lenalidomide in lower-risk patients. NCI: aspirin suffices for patients without extra DVT risk factors; "stronger anticoagulants should be considered for patients with multiple risk factors."
First-line for symptomatic PAD — and the point is the heart and brain, not the leg: single antiplatelet therapy (clopidogrel 75 mg daily or aspirin 75–325 mg daily) reduces MI, ischemic stroke, and vascular death in this systemic atherosclerosis (ACC/AHA 2024, Class 1). The exam trap: it is single antiplatelet therapy — dual therapy (P2Y12 + low-dose aspirin) is reasonable only for 1–6 months after endovascular revascularization and about 1 month after a prosthetic bypass graft, because synthetic conduits are more thrombogenic. After a stent, antiplatelets keep clots from forming and narrowing the treated artery, and patients take them exactly as prescribed. Note the one anticoagulant with a PAD indication: low-dose rivaroxaban 2.5 mg twice daily plus aspirin 81 mg reduces cardiovascular and limb events in symptomatic PAD without high bleeding risk; full-intensity anticoagulation without another indication such as AF is rated Harm.
Low-dose aspirin prevents clots in most patients. NCI: low-dose aspirin daily "unless contraindicated by major bleeding or gastric intolerance"; StatPearls (2026): "low-dose aspirin is recommended for most patients without contraindications." Not when platelets exceed 1 million/µL (acquired von Willebrand disease), and higher doses raise bleeding risk. It also relieves erythromelalgia.
[Secondary Raynaud’s with ischemic ulceration] StatPearls: low-dose aspirin daily for "patients with secondary Raynaud phenomenon and a history of ischemic ulceration."
First-line secondary prevention for noncardioembolic ischemic stroke and TIA: aspirin within 24–48 h of onset — but delayed until 24 hours after IV alteplase (post-lysis bleeding risk). For minor stroke or high-risk TIA, dual antiplatelet therapy (aspirin + clopidogrel) starts within 24 h and runs 3 weeks to 1 month, then drops to a single agent; ticagrelor is the alternative in CYP2C19 loss-of-function carriers.
Mostly what VTE is not treated with: platelets dominate arterial thrombosis, so antiplatelets are the cornerstone there — not in fibrin-rich venous clots. Even for prophylaxis, aspirin alone is not generally recommended — it beats placebo but has not been compared with the heparins; its niche is hybrid therapy, taking over at discharge after other agents are used in hospital.
See also
Slow heart rate & lower BP by blocking β-adrenergic receptors. Watch for bradycardia.
Lower BP by blocking angiotensin conversion. Classic dry cough & angioedema risk.
Lower LDL cholesterol via HMG-CoA reductase inhibition. Monitor for myopathy.
Injectable antibodies that protect the liver’s LDL receptors, cutting LDL cholesterol by about half and lowering cardiovascular events. Given subcutaneously every 2–4 weeks.
PPAR-α agonists that mainly lower triglycerides — used with diet for severe hypertriglyceridemia — with muscle, gallbladder, liver and kidney risks, highest for gemfibrozil combined with a statin.
Non-absorbed resins that trap bile acids in the gut, forcing the liver to use cholesterol and pull LDL from the blood. Constipation, drug binding and rising triglycerides are the issues to manage.
Sources
- BRILINTA (ticagrelor) — boxed warnings (bleeding; aspirin > 100 mg reduces efficacy), FDA label — FDA / DailyMed
- Antiplatelet Medications — mechanisms, DAPT, adverse effects & contraindications — StatPearls (NCBI)
- Aspirin — COX-1 mechanism, 7–10-day platelet effect, GI & bleeding risk — StatPearls (NCBI)
- Open RN Nursing Pharmacology — Ch. 6 (antiplatelet grid: give with food, bleeding, 7–10 days) — Open RN (NCBI Bookshelf)
- Clopidogrel — CYP2C19 activation, poor-metabolizer boxed warning — StatPearls (NCBI)
- PLAVIX (clopidogrel) — boxed warning (CYP2C19), contraindications, PPIs — DailyMed (NLM)
- EFFIENT (prasugrel) — boxed warning (bleeding), contraindications — DailyMed (NLM)
- Bayer Aspirin Regimen (aspirin) — drug facts — DailyMed (NLM)
- ECOTRIN (aspirin) — drug facts (stomach bleeding, allergy alert) — DailyMed (NLM)
- Thrombosis — arterial vs venous thrombosis — StatPearls (NCBI)
- Intracranial Hemorrhage Overview — presenting signs — StatPearls (NCBI)
- StatPearls: Hypercoagulability — StatPearls (NCBI)
- StatPearls: Anterior Myocardial Infarction — StatPearls (NCBI)
- StatPearls: Virchow Triad — StatPearls (NCBI)
- StatPearls: Angioplasty — StatPearls (NCBI)
- StatPearls: Stent Thrombosis — StatPearls (NCBI)
- StatPearls: Cardiac Risk Assessment — StatPearls (NCBI)
- Eptifibatide injection (Baxter) — FDA label: GP IIb/IIIa mechanism, contraindications, bleeding, thrombocytopenia — FDA / DailyMed
- Eptifibatide — pharmacokinetics, thrombocytopenia, monitoring — StatPearls (NCBI)
- Glycoprotein IIb/IIIa Inhibitors — mechanism, IV-only agents — StatPearls (NCBI)
- Aggrastat (tirofiban) — FDA label: contraindications, thrombocytopenia monitoring, renal clearance — FDA / DailyMed
- Kengreal (cangrelor) — FDA label: reversible IV P2Y12 block, transition to oral P2Y12 inhibitors — FDA / DailyMed
- Cangrelor — no metabolic activation, monitoring — StatPearls (NCBI)
- Cilostazol tablets (Apotex) — FDA label: boxed heart-failure contraindication, PDE III mechanism, interactions — FDA / DailyMed
- Cilostazol — monitoring for blood dyscrasia — StatPearls (NCBI)
- Dipyridamole tablets (Amneal) — FDA label: adenosine mechanism, valve-replacement indication, stress-test hold — FDA / DailyMed
- Aspirin and extended-release dipyridamole (Amneal) — FDA label: stroke prevention, headache, bleeding — FDA / DailyMed
- Dipyridamole — mechanism and pharmacokinetics — StatPearls (NCBI)
- The use of stems in the selection of INN (2018) — -grel, -fiban, -tide — World Health Organization
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.